Recovering scientist turned early stage VC A biotech optimist fighting gravity

Five Questions To Ask Your Investors Before You Take Their Money
April 22, 2015

This blog was written by Mike Gilman, CEO of Padlock Therapeutics and Atlas EIR, as part of the “From the Trenches” feature of LifeSciVC. Padlock Therapeutics is my second startup, and it’s not nearly as scary as the first one. Not

4 Comments

Data Snapshot: Venture-Backed Biotech Financing Riding High
April 21, 2015

Biotech venture funding metrics continue at historic highs, highlighting that the robust financing environment in the public markets continues to fuel the private markets as well. Last week the quarterly Thomson Reuters data on venture capital funding came out via

Leave a comment

Atlas X: Accelerating Biotech Venture Creation
April 17, 2015

Earlier this week Atlas Venture closed Fund X at $280M, completing our transition to a biotech-only venture firm. After announcing the split of our life science and technology franchises in October 2014 (here), we embarked on the hard work of

Leave a comment

Nucleic Acid Therapeutics Coming of Age
April 1, 2015

This blog was written by Bill Marshall, CEO of miRagen Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. The opportunity to use nucleic acids as therapeutic agents is extremely exciting. Creating drugs that affect protein targets that are

Leave a comment

Seed Stage Investing in Talent
March 26, 2015

A few weeks ago, Michael Gladstone wrote a blog, here, about infusing young blood into the ‘C’ suite of biotech. I thought he made a number of important points and great suggestions about the topic. Today, I’d like to expand

2 Comments

Biotech IPO Performance: Discerning Market Or Rising Tide?
March 20, 2015

As anyone following the biotech sector knows, the market for new public offerings has been incredibly strong over the past couple years. And the larger cap stocks in the sector have also outperformed, propelled by product launches and exciting clinical

Leave a comment

Finding Success In Failing Early: All About Execution
March 18, 2015

In a period of surging optimism for our industry, it’s easy to forget that historically most of the therapeutic projects we undertake don’t make it to the market (see the data here if you absolutely have to remind yourself of

1 Comment

Biotech CEOs: Observations In Thermodynamics And Kinetics
March 16, 2015

A great CEO makes all the difference, and a poor one destroys a ton of value. But recruiting great CEOs is often hard, especially when picking, as is most often the case, from a list of potential first-time CEOs. How

4 Comments

Buying Time in 2014: Comparative Holding Periods For VC-Backed M&A Events
March 13, 2015

Over the past decade, in contrast to widely held misperceptions, the Biotech sector has witnessed time-to-IPO metrics very similar to other venture sectors, as I recently blogged on regarding the 2014 IPO Class (here). What wasn’t covered in the prior post was

1 Comment

Nature Biotech Honors Some Of 2014’s Best Academic Startups
March 6, 2015

This afternoon Nature Biotechnology published its annual review of the “some of the best that academic research had to offer the startup world in 2014.” The article, in the March 2015 issue, covers the editors’ selections of the top startups

Leave a comment

Rare Diseases, Rare Opportunities
March 4, 2015

Last week on February 28th – as I sat down to write this short blog– was Rare Disease Day 2015. Rare diseases, and there are estimated to be 7000 of them, impact almost 30 million people in the US alone, according to

2 Comments

Tortoise & Hare Revisited: “Time To IPO” For VC-Backed Startups
February 24, 2015

Getting a drug from discovery to market requires more than a dozen years, so you just can’t do biotech in a 10-year venture fund – it just takes too long, right?  Fortunately, wrong.  The data just don’t support this premise, although this

Leave a comment